Melane Sampson, Author at BioTuesdays

Developments

Surmodics reports outcomes from registry evaluating Pounce in limb ischemia

Surmodics (NASDAQ: SRDX) has announced outcomes from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia in the PROWL registry study evaluating its Pounce thrombectomy platform. The...

November 5, 2025

Developments

Wellgistics enters LOI to acquire Kare RX digital hub

Wellgistics Health (NASDAQ: WGRX) has announced that it has entered into a non-binding letter of intent (LOI) to acquire Kare RX—an AI-based digital hub—from closely held Kare PharmaTech. According to Wellgistics, Kare...

November 5, 2025

Developments

GeoVax connects IDSA COVID-19 guidance to GEO-CM04S1 clinical data

GeoVax Labs (NASDAQ: GOVX) has highlighted that its recent Phase 2 findings for GEO-CM04S1 aligns with Infectious Diseases Society of America (IDSA) guidelines prioritizing vaccination for immunocompromised individuals...

October 29, 2025

Developments

APO grants new patent for Moleculin’s Annamycin

Moleculin Biotech (NASDAQ: MBRX) has announced that the Australian Patent Office (APO) has granted a patent with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity...

October 29, 2025

Feature

Immuneering outpacing cancer with a novel approach to improving overall survival

Immuneering (NASDAQ: IMRX) is challenging conventional approaches of sustained inhibition in oncology by pioneering a novel class of therapies designed to outsmart cancer’s ability to adapt. With a proprietary platform...

October 28, 2025

Executive Moves

Mary-Elizabeth Gifford joins Clearmind as Chief of Global Impact

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the appointment of Mary-Elizabeth Gifford as chief of global impact. Prior to joining Clearmind, Gifford served as chief of global impact at Psyence BioMed, a...

October 27, 2025

Developments

PharmaJet’s Tropis ID selected for Pakistan’s polio campaign

Closely held PharmaJet has announced that its WHO prequalified Tropis ID Needle-free Injection System will be used exclusively in Pakistan’s latest polio immunization campaign to deliver vaccines to 1.8 million children...

October 24, 2025

Developments

CorMedix receives innovative technology designation for DefenCath

CorMedix (NASDAQ: CRMD) has announced that its DefenCath antimicrobial catheter lock solution (CLS) has received innovative technology designation from closely held Vizient—a heathcare performance improvement company...

October 23, 2025

Developments

MAIA details exceptional survival in third-line NSCLC at ESMO

MAIA Biotechnology (NYSE American: MAIA) has announced highlights from a presentation at the European Society for Medical Oncology (ESMO) Congress 2025 held in Berlin, Germany, showcasing its ongoing Phase 2 and Phase 3...

October 23, 2025

Executive Moves

Three key appointments strengthen Amphista’s clinical development capabilities

Closely held Amphista Therapeutics has announced the appointments of Dr. Lisa Butler as SVP of clinical operations, Dr. Alexandra Sevko as VP of translational science, and Nicola Lindsay as head of project and portfolio...

October 23, 2025

Author - Melane Sampson

Surmodics reports outcomes from registry evaluating Pounce in limb ischemia

Wellgistics enters LOI to acquire Kare RX digital hub

GeoVax connects IDSA COVID-19 guidance to GEO-CM04S1 clinical data

APO grants new patent for Moleculin’s Annamycin

Immuneering outpacing cancer with a novel approach to improving overall survival

Mary-Elizabeth Gifford joins Clearmind as Chief of Global Impact

PharmaJet’s Tropis ID selected for Pakistan’s polio campaign

CorMedix receives innovative technology designation for DefenCath

MAIA details exceptional survival in third-line NSCLC at ESMO

Three key appointments strengthen Amphista’s clinical development capabilities

Subscribe